BioCryst Pharmaceuticals BCRX Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's long-term debt?
- BioCryst Pharmaceuticals (BCRX) reported long-term debt of $395.2M in Q1 2026.
- How has BioCryst Pharmaceuticals's long-term debt changed year-over-year?
- BioCryst Pharmaceuticals's long-term debt increased by 25.3% year-over-year, from $315.41M to $395.2M.
- What is the long-term trend for BioCryst Pharmaceuticals's long-term debt?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's long-term debt has grown at a -100.0% compound annual growth rate (CAGR), from $119.74M to $0.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.